Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 16, Number 3—March 2010

Research

Vaccine Preventability of Meningococcal Clone, Greater Aachen Region, Germany

Johannes EliasComments to Author , Leo M. Schouls, Ingrid van de Pol, Wendy C. Keijzers, Diana R. Martin, Anne Glennie, Philipp Oster, Matthias Frosch, Ulrich Vogel1, and Arie van der Ende1
Author affiliations: University of Wuerzburg, Wuerzburg, Germany (J. Elias, M. Frosch, U. Vogel); National Institute for Public Health and Environment (RIVN), Bilthoven, the Netherlands (L.M. Schouls, I. van de Pol); Academic Medical Center, Amsterdam, the Netherlands (W.C. Keijzers, A. van der Ende); Institute of Environmental Science and Research, Porirua, New Zealand (D.R. Martin, A. Glennie); Novartis Vaccines, Siena, Italy (P. Oster)

Main Article

Table 2

Serum bactericidal antibody titers before and after vaccination with MeNZB against German strain DE9686, Greater Aachen Region, Germany, 2001–2006*

Age group No. vaccinees Before After 4-fold rise >8 post
8–12 y 1 12 1,727
2 3 104
3 189 406
4 50 296
5 229 729
6 23 175
7 9 84
8 2 213
9 2 77
10 2 55
18–24 mo 11 2 214
12 4 45
13 2 109
14 7 92
15 2 306
16 6 431
17 2 216
18 3 44
19 3 218
20 2 171

*– represents cases where conditions 4-fold rise and >8 post are false. Arrows represent cases where conditions 4-fold rise and >8 post are true.

Main Article

1These authors contributed equally to this article.

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO